Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. cut its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 52.0% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 12,364 shares of the company’s stock after selling 13,417 shares during the period. Principal Financial Group Inc.’s holdings in Sana Biotechnology were worth $51,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp raised its holdings in Sana Biotechnology by 26.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 431,744 shares of the company’s stock valued at $2,357,000 after acquiring an additional 90,423 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Sana Biotechnology by 20.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock valued at $163,000 after buying an additional 5,090 shares during the period. Rhumbline Advisers lifted its holdings in shares of Sana Biotechnology by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 181,903 shares of the company’s stock worth $993,000 after acquiring an additional 25,056 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Sana Biotechnology by 36.7% in the 2nd quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock valued at $202,000 after buying an additional 9,940 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Sana Biotechnology during the second quarter worth about $100,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SANA. JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Sana Biotechnology in a research report on Wednesday, November 27th.

Sana Biotechnology Stock Down 5.7 %

NASDAQ:SANA opened at $1.65 on Wednesday. The firm’s fifty day simple moving average is $2.38 and its 200-day simple moving average is $4.07. The stock has a market cap of $368.39 million, a PE ratio of -1.18 and a beta of 1.45. Sana Biotechnology, Inc. has a fifty-two week low of $1.52 and a fifty-two week high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. Equities analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.